Skip to main content
. 2023 Jun 27;12(1):2227510. doi: 10.1080/2162402X.2023.2227510

Figure 5.

Figure 5.

TLR3 agonists restore the efficacy of chemotherapy in defective Anxa1/Fpr1 signaling in fibrosarcoma-bearing mice. (a) Scheme of the in vivo tumor growth experiment. (b) Murine MCA205 cells WT or Anxa1−/− were inoculated s.c. into immunocompetent C57BL/6 WT or Fpr1−/− mice. When tumor became palpable (with a size inferior to 80 mm2) mice received 5.17 mg/kg i.P. mitoxantrone (MTX), 50 mg/kg i.P. cyclophosphamide (CTX), 50 μg/mouse, i.P. poly(I:C) (pIC), 150 µg/mouse i.P. poly(A:U) pAU, and 200 µg/mouse or 2 mg/mouse i.P. TL-532 (injected at days 1, 4, and 7 post treatment), or an equivalent volume of NaCl 0.9%. Tumor growth was routinely assessed using a digital caliper. Of note, data from the right panel represent results of two experiments yielding similar results.